| NCT04173494 |
A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Patients (MOMENTUM) |
https://ClinicalTrials.gov/show/NCT04173494 |
Recruiting |
Sierra Oncology, Inc. |
2021-12-31 |
| NCT03289910 |
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia |
https://ClinicalTrials.gov/show/NCT03289910 |
Recruiting |
National Cancer Institute (NCI) |
2021-06-01 |
| NCT03232177 |
Anagre Cap. in Patients With High-Risk Essential Thrombocythemia |
https://ClinicalTrials.gov/show/NCT03232177 |
Recruiting |
Yuhan Corporation |
2021-06-30 |
| NCT03212053 |
Prospective Study of Different Biological Tests (Multiplate, ROTEM) in a Cohort of Patients Followed for Essential Thrombocytemia (ET) |
https://ClinicalTrials.gov/show/NCT03212053 |
Completed |
Hospices Civils de Lyon |
2019-08-08 |
| NCT03136185 |
IMG-7289 in Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT03136185 |
Recruiting |
Imago BioSciences,Inc. |
2020-12-31 |
| NCT03123588 |
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) |
https://ClinicalTrials.gov/show/NCT03123588 |
Recruiting |
Incyte Corporation |
2020-05-31 |
| NCT03116542 |
18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia |
https://ClinicalTrials.gov/show/NCT03116542 |
Recruiting |
Hamad Medical Corporation |
2020-05-31 |
| NCT03065400 |
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms |
https://ClinicalTrials.gov/show/NCT03065400 |
Completed |
Icahn School of Medicine at Mount Sinai |
2020-05-28 |
| NCT02966353 |
Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. |
https://ClinicalTrials.gov/show/NCT02966353 |
Completed |
Novartis |
2018-07-24 |
| NCT02962388 |
The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line |
https://ClinicalTrials.gov/show/NCT02962388 |
Active, not recruiting |
French Innovative Leukemia Organisation |
2018-06-07 |
| NCT02611973 |
Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia |
https://ClinicalTrials.gov/show/NCT02611973 |
Recruiting |
Assistance Publique - Hôpitaux de Paris |
2019-11-30 |
| NCT03165734 |
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis |
https://ClinicalTrials.gov/show/NCT03165734 |
Recruiting |
CTI BioPharma |
2022-07-31 |
| NCT01433445 |
Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis |
https://ClinicalTrials.gov/show/NCT01433445 |
Completed |
Novartis |
2020-06-22 |
| NCT02556931 |
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies |
https://ClinicalTrials.gov/show/NCT02556931 |
Active, not recruiting |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2021-07-31 |
| NCT02515630 |
Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) |
https://ClinicalTrials.gov/show/NCT02515630 |
Completed |
Sierra Oncology, Inc. |
2017-07-18 |
| NCT02436135 |
Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease |
https://ClinicalTrials.gov/show/NCT02436135 |
Completed |
Gilead Sciences |
2017-11-20 |
| NCT02407080 |
Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia |
https://ClinicalTrials.gov/show/NCT02407080 |
Completed |
Icahn School of Medicine at Mount Sinai |
2018-12-19 |
| NCT02386800 |
CINC424A2X01B Rollover Protocol |
https://ClinicalTrials.gov/show/NCT02386800 |
Recruiting |
Novartis |
2025-09-17 |
| NCT02311569 |
Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation |
https://ClinicalTrials.gov/show/NCT02311569 |
Completed |
Swiss Group for Clinical Cancer Research |
2016-12-31 |
| NCT02129101 |
Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies |
https://ClinicalTrials.gov/show/NCT02129101 |
Completed |
Mayo Clinic |
2016-12-31 |
| NCT02125318 |
A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders |
https://ClinicalTrials.gov/show/NCT02125318 |
Completed |
Galena Biopharma, Inc. |
2016-05-31 |
| NCT02124746 |
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia |
https://ClinicalTrials.gov/show/NCT02124746 |
Completed |
Sierra Oncology, Inc. |
2018-12-06 |
| NCT02101268 |
Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF |
https://ClinicalTrials.gov/show/NCT02101268 |
Completed |
Sierra Oncology, Inc. |
2016-07-28 |
| NCT02098161 |
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis |
https://ClinicalTrials.gov/show/NCT02098161 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-12-31 |
| NCT02087059 |
A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis |
https://ClinicalTrials.gov/show/NCT02087059 |
Completed |
Novartis |
2015-03-31 |
| NCT02076815 |
Anagrelide Retard in Essential Thrombocythemia |
https://ClinicalTrials.gov/show/NCT02076815 |
Completed |
AOP Orphan Pharmaceuticals AG |
2015-02-28 |
| NCT01369498 |
Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01369498 |
Completed |
Gilead Sciences |
2014-06-05 |
| NCT01981850 |
A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01981850 |
Active, not recruiting |
Promedior, Inc. |
2017-08-30 |
| NCT01969838 |
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01969838 |
Completed |
Sierra Oncology, Inc. |
2016-09-12 |
| NCT01816256 |
Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms |
https://ClinicalTrials.gov/show/NCT01816256 |
Completed |
University Health Network, Toronto |
2019-03-11 |
| NCT01787552 |
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF |
https://ClinicalTrials.gov/show/NCT01787552 |
Completed |
Novartis |
2018-04-10 |
| NCT01787487 |
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm |
https://ClinicalTrials.gov/show/NCT01787487 |
Recruiting |
M.D. Anderson Cancer Center |
2020-07-26 |
| NCT01760655 |
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01760655 |
Recruiting |
Thomas Jefferson University |
2021-03-31 |
| NCT01692366 |
Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly |
https://ClinicalTrials.gov/show/NCT01692366 |
Completed |
Sanofi |
2014-03-31 |
| NCT01588015 |
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01588015 |
Active, not recruiting |
City of Hope Medical Center |
2021-11-30 |
| NCT01558739 |
Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) |
https://ClinicalTrials.gov/show/NCT01558739 |
Completed |
Novartis |
2014-01-31 |
| NCT01520220 |
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms |
https://ClinicalTrials.gov/show/NCT01520220 |
Completed |
Eli Lilly and Company |
2015-06-26 |
| NCT01493414 |
INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. |
https://ClinicalTrials.gov/show/NCT01493414 |
Completed |
Novartis |
2017-01-26 |
| NCT01467661 |
Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia |
https://ClinicalTrials.gov/show/NCT01467661 |
Completed |
Shire |
2015-05-01 |
| NCT01445769 |
Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01445769 |
Completed |
Incyte Corporation |
2013-03-31 |
| NCT01423851 |
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF |
https://ClinicalTrials.gov/show/NCT01423851 |
Active, not recruiting |
NS Pharma, Inc. |
2020-11-30 |
| NCT01420783 |
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia |
https://ClinicalTrials.gov/show/NCT01420783 |
Completed |
Sanofi |
2012-11-30 |
| NCT01392443 |
Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF |
https://ClinicalTrials.gov/show/NCT01392443 |
Completed |
Novartis |
2017-10-31 |
| NCT01387763 |
A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms |
https://ClinicalTrials.gov/show/NCT01387763 |
Active, not recruiting |
Odense University Hospital |
2020-01-31 |
| NCT01384513 |
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01384513 |
Recruiting |
Thomas Jefferson University |
2020-12-31 |
| NCT01348490 |
Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF) |
https://ClinicalTrials.gov/show/NCT01348490 |
Completed |
Incyte Corporation |
2018-12-19 |
| NCT03878524 |
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial |
https://ClinicalTrials.gov/show/NCT03878524 |
Recruiting |
OHSU Knight Cancer Institute |
2022-02-27 |
| NCT04282187 |
Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms |
https://ClinicalTrials.gov/show/NCT04282187 |
Recruiting |
University of Washington |
2024-11-11 |
| NCT04262141 |
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) |
https://ClinicalTrials.gov/show/NCT04262141 |
Recruiting |
University of Miami |
2023-08-31 |
| NCT04226950 |
Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in the Treatment of Childhood Essential Thrombocythemia |
https://ClinicalTrials.gov/show/NCT04226950 |
Recruiting |
Institute of Hematology & Blood Diseases Hospital |
2022-07-20 |
| NCT04081220 |
Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2 |
https://ClinicalTrials.gov/show/NCT04081220 |
Recruiting |
The University of Texas Health Science Center at San Antonio |
2022-01-31 |
| NCT03972943 |
CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia |
https://ClinicalTrials.gov/show/NCT03972943 |
Recruiting |
University of Utah |
2024-05-01 |
| NCT03952039 |
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib |
https://ClinicalTrials.gov/show/NCT03952039 |
Recruiting |
Celgene |
2021-11-24 |
| NCT03935555 |
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib |
https://ClinicalTrials.gov/show/NCT03935555 |
Recruiting |
Samus Therapeutics, Inc. |
2020-05-15 |
| NCT03907436 |
The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase |
https://ClinicalTrials.gov/show/NCT03907436 |
Completed |
University of California, Irvine |
2019-10-01 |
| NCT03895112 |
MPN-RC 118 AVID200 in Myelofibrosis |
https://ClinicalTrials.gov/show/NCT03895112 |
Recruiting |
Icahn School of Medicine at Mount Sinai |
2021-03-31 |
| NCT03878199 |
Ruxolitinib and Daunorubicin (CPX-351) in Treating Patients With Secondary Acute Myeloid Leukemia Transformed From Myeloproliferative Neoplasms |
https://ClinicalTrials.gov/show/NCT03878199 |
Recruiting |
OHSU Knight Cancer Institute |
2021-12-31 |
| NCT03869476 |
Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. |
https://ClinicalTrials.gov/show/NCT03869476 |
Recruiting |
University Hospital, Angers |
2023-06-30 |
| NCT03862157 |
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT03862157 |
Recruiting |
M.D. Anderson Cancer Center |
2024-01-01 |
| NCT03755518 |
An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib |
https://ClinicalTrials.gov/show/NCT03755518 |
Recruiting |
Celgene |
2022-05-19 |
| NCT03662126 |
KRT-232 in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK Inhibitor |
https://ClinicalTrials.gov/show/NCT03662126 |
Recruiting |
Kartos Therapeutics, Inc. |
2021-08-01 |
| NCT03627403 |
Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors |
https://ClinicalTrials.gov/show/NCT03627403 |
Recruiting |
University of Utah |
2024-03-14 |
| NCT03566446 |
CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms |
https://ClinicalTrials.gov/show/NCT03566446 |
Active, not recruiting |
Herlev Hospital |
2020-02-20 |
| NCT03441113 |
Extended Access of Momelotinib in Adults With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT03441113 |
Enrolling by invitation |
Sierra Oncology, Inc. |
2024-12-31 |
| NCT01259856 |
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) |
https://ClinicalTrials.gov/show/NCT01259856 |
Completed |
Icahn School of Medicine at Mount Sinai |
2017-06-30 |
| NCT01259817 |
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) |
https://ClinicalTrials.gov/show/NCT01259817 |
Completed |
Icahn School of Medicine at Mount Sinai |
2016-12-31 |
| NCT01243073 |
Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera |
https://ClinicalTrials.gov/show/NCT01243073 |
Completed |
Geron Corporation |
2013-10-31 |
| NCT01236638 |
Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) |
https://ClinicalTrials.gov/show/NCT01236638 |
Completed |
Sierra Oncology, Inc. |
2014-06-30 |
| NCT01230775 |
Anagrelide Retard vs. Placebo: Efficacy and Safety in “At-risk” Patients With Essential Thrombocythaemia |
https://ClinicalTrials.gov/show/NCT01230775 |
Completed |
AOP Orphan Pharmaceuticals AG |
2015-01-31 |
| NCT01214915 |
Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia |
https://ClinicalTrials.gov/show/NCT01214915 |
Completed |
Shire |
2012-10-24 |
| NCT01134120 |
A Study in Myeloproliferative Disorders |
https://ClinicalTrials.gov/show/NCT01134120 |
Completed |
Eli Lilly and Company |
2014-04-30 |
| NCT01065038 |
Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia |
https://ClinicalTrials.gov/show/NCT01065038 |
Completed |
AOP Orphan Pharmaceuticals AG |
NA |
| NCT01053494 |
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer |
https://ClinicalTrials.gov/show/NCT01053494 |
Completed |
Wake Forest University Health Sciences |
2012-02-29 |
| NCT00946270 |
Pomalidomide for Myelofibrosis Patients |
https://ClinicalTrials.gov/show/NCT00946270 |
Completed |
M.D. Anderson Cancer Center |
2018-05-22 |
| NCT00935987 |
Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) |
https://ClinicalTrials.gov/show/NCT00935987 |
Completed |
Sierra Oncology, Inc. |
2012-04-30 |
| NCT00910728 |
Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases |
https://ClinicalTrials.gov/show/NCT00910728 |
Completed |
AstraZeneca |
2012-03-31 |
| NCT00890747 |
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
https://ClinicalTrials.gov/show/NCT00890747 |
Completed |
National Cancer Institute (NCI) |
2011-05-31 |
| NCT01423058 |
Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01423058 |
Completed |
Sierra Oncology, Inc. |
2014-06-30 |
| NCT04051307 |
Dual Vaccine Trial in Myeloproliferative Neoplasms |
https://ClinicalTrials.gov/show/NCT04051307 |
Recruiting |
Herlev Hospital |
2022-07-10 |
| NCT02577926 |
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia |
https://ClinicalTrials.gov/show/NCT02577926 |
Recruiting |
RWTH Aachen University |
2020-12-31 |
| NCT03373877 |
Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis |
https://ClinicalTrials.gov/show/NCT03373877 |
Active, not recruiting |
Samus Therapeutics, Inc. |
2020-10-31 |
| NCT04254978 |
IMG-7289 in Patients With Essential Thrombocythemia |
https://ClinicalTrials.gov/show/NCT04254978 |
Recruiting |
Imago BioSciences,Inc. |
2022-05-31 |
| NCT00745550 |
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis |
https://ClinicalTrials.gov/show/NCT00745550 |
Completed |
S*BIO |
2012-01-31 |
| NCT00718159 |
Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT00718159 |
Completed |
Eli Lilly and Company |
2011-12-31 |
| NCT00588991 |
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders |
https://ClinicalTrials.gov/show/NCT00588991 |
Active, not recruiting |
National Cancer Institute (NCI) |
2014-02-01 |
| NCT00586651 |
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis |
https://ClinicalTrials.gov/show/NCT00586651 |
Completed |
Teva Pharmaceutical Industries |
2009-10-31 |
| NCT00509899 |
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis |
https://ClinicalTrials.gov/show/NCT00509899 |
Completed |
Incyte Corporation |
2007-12-31 |
| NCT00489203 |
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00489203 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00445744 |
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome |
https://ClinicalTrials.gov/show/NCT00445744 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-06-30 |
| NCT00413634 |
The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET) |
https://ClinicalTrials.gov/show/NCT00413634 |
Completed |
Shire |
2008-01-31 |
| NCT00397813 |
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders |
https://ClinicalTrials.gov/show/NCT00397813 |
Completed |
Fred Hutchinson Cancer Research Center |
2017-09-30 |
| NCT00381550 |
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia |
https://ClinicalTrials.gov/show/NCT00381550 |
Completed |
National Cancer Institute (NCI) |
2011-03-31 |
| NCT00357305 |
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders |
https://ClinicalTrials.gov/show/NCT00357305 |
Completed |
National Cancer Institute (NCI) |
2011-11-30 |
| NCT00227591 |
Lenalidomide and Prednisone in Treating Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT00227591 |
Completed |
National Cancer Institute (NCI) |
2010-12-31 |
| NCT00202644 |
A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients |
https://ClinicalTrials.gov/show/NCT00202644 |
Completed |
Shire |
2015-12-15 |
| NCT00175838 |
Primary Thrombocythaemia 1 Trial |
https://ClinicalTrials.gov/show/NCT00175838 |
Completed |
University of Cambridge |
2016-11-30 |
| NCT00112593 |
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer |
https://ClinicalTrials.gov/show/NCT00112593 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-11-30 |
| NCT00089011 |
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00089011 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-03-31 |
| NCT00047190 |
Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia |
https://ClinicalTrials.gov/show/NCT00047190 |
Completed |
National Cancer Institute (NCI) |
2007-04-30 |
| NCT00039416 |
Imatinib Mesylate in Treating Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT00039416 |
Completed |
National Cancer Institute (NCI) |
2007-08-31 |
| NCT00025415 |
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00025415 |
Completed |
National Cancer Institute (NCI) |
2005-01-31 |
| NCT00052520 |
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00052520 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-04-30 |